A Panel of Angiogenic Factors for Early Bladder Cancer Detection: Enzyme Immunoassay and Western Blot

Eissa, Sanaa; Swellam, Menha; Labib, Randa; Elzayat, Tarek; Ahmady, Omar El

doi:10.1016/j.juro.2008.10.102

Cited by 22 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiogenin binds to a cell surface and these complex results in plasmin generation, which directly degrades the extracellular matrix facilitating cell migration and invasion [9]. When we compared the correlation between the positivity rate of urinary angiogenin and the different clinicopathological factors in the malignant group, Eissa et al found that angiogenin was highly expressed in patients with bladder SCC vs. bladder TCC (76% vs. 73%) [9]. In our study angiogenin was also highly expressed in SCC vs. TCC of bladder cancer (100% vs. 60.46%) with significance vale (p= 0.041).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer

Shabayek

sayed

Attaia

et al. 2014

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Abstract-Bladder carcinoma is an important worldwide health problem. Both cystoscopy and urine cytology used in detecting bladder cancer suffer from drawbacks where cystoscopy is an invasive method and urine cytology shows low sensitivity in low grade tumors. This study validates easier and less time-consuming techniques to evaluate the value of combined use of angiogenin and clusterin in comparison and combination with voided urine cytology in the detection of bladder cancer patients. This study includes malignant (bladder cancer patients, n= 50), benign (n=20) and healthy (n=20) groups. The studied groups were subjected to cystoscopic examination, detection of bilharzial antibodies, urine cytology, and estimation of urinary angiogenin and clusterin by ELISA. The overall sensitivity and specificity were 66% and 75% for angiogenin, 70% and 82.5% for clusterin and 46% and 80% for voided urine cytology. Combined sensitivity of angiogenin and clusterin with urine cytology increased from 82 to 88%.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Since it may have a role in the development and evolution of carcinomas, it is a particularly interesting molecule to study as a potential tumor marker and / or prognostic indicator for urinary bladder cancer [9].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer

Shabayek

sayed

Attaia

et al. 2014

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Each urine sample was centrifuged and then the urinary sediment was washed with PBS. A portion of the pellet was used for cytological and microscopic examinations (16) and the other portion was treated with protease inhibitor cocktail (8) and stored at À80 C for further processing to extract DNA to be used for detection of methylated APC and RARb 2 .…”

Section: Collection Of Samplesmentioning

confidence: 99%

“…Alternatively, urine cytology is known for its good specificity but poor sensitivity for early stages and low grades. An array of urine markers were evaluated to improve the diagnostic ability of urine cytology and, perhaps, to reduce the need for frequent cystoscopies during follow-up, especially in those with low-risk disease (4)(5)(6)(7)(8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Aberrant Methylation ofRARβ2andAPCGenes in Voided Urine as Molecular Markers for Early Detection of Bilharzial and Nonbilharzial Bladder Cancer

Eissa

Swellam²,

El-Khouly³

et al. 2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Background: Bladder cancer cells illustrate major disruptions in their DNA methylation patterns as compared with normal ones. Authors aimed to identify epigenetic molecular markers in urine for early detection of bladder cancer.Materials and Methods: We retrospectively analyzed the methylation status of RARb 2 and APC genes in urine samples from 210 bladder cancer patients, 61 patients with benign urological diseases, and 49 healthy volunteers by using methylation-specific PCR.Results: Methylated RARb 2 and APC were significantly higher in bladder cancer patients (62.8%, 59.5%) than benign (16.4%, 5%) but not detected in healthy volunteers (0%) at (P < 0.0001). Both methylated genes showed no significant difference among clinicopathologic factors; however, they were detected in all grades and stages. Among the 128 patients with bilharzial bladder cancer, 94 (73.4%) showed methylated RARb 2 and 86 (67.2%) showed methylated APC. Homoplasmic methylation pattern of both genes were only detected in bilharzial bladder cancer cases. Both sensitivities and specificities of the methylated genes for bladder cancer detection were superior to urine cytology and when altogether combined, the sensitivities improved to (91.8%), (93.5%), (91.9%), and (80.9%) in detection of: bladder cancer, non-muscle invasive bladder cancer, low-grade tumors, and bilharzial associated bladder cancer, respectively.Conclusion: Thus, methylated RARb 2 and APC genes might be valuable urinary molecular markers for early detection of bilharzial and nonbilharzial bladder cancer. Cancer Epidemiol Biomarkers Prev; 20(8); 1657-64. Ó2011 AACR.

show abstract

“…Although uri-nary cytology is widely used for screening for bladder cancer, it is sometimes difficult to judge cytologic specimens, particularly for low-grade cancers [5]. Therefore new, noninvasive methods for bladder cancer detection would open new possibilities in diagnosis and monitoring [6], as well as in screening of groups at risk such as bilharzial infested patients [7][8][9]. An ideal test to monitor bladder cancer should be objective, noninvasive, easy to administer and interpret and have high sensitivity and specificity.…”

Section: Introductionmentioning

confidence: 99%

The Value of Combined Use of Survivin mRNA and Matrix Metalloproteinase 2 and 9 for Bladder Cancer Detection in Voided Urine

et al. 2013

Self Cite

View full text Add to dashboard Cite

Abstract. Objective:In a trial to improve the diagnostic efficacy of conventional urine cytology we determine survivin RNA and matrix metalloproteinase 2 and 9 in urine of bladder cancer cases. Method: Voided urine specimens were collected from patients with histologically confirmed bladder urothelial carcinoma (Group 1; n = 46), urological patients without urothelial carcinoma (Group 2; n = 20), and healthy volunteers (Group 3; n = 20). Urine cytology, survivin RNA was estimated by qualitative nested RT-PCR and MMP-2, MMP-9 activity were detected by gelatin zymography. The expression of survivin RNA and matrix metalloproteinase 2 and 9 in bladder cancer was compared with benign and normal cases. Results: Positivity rates of survivin RNA and MMPs zymography were significantly different among the 3 groups. Urine survivin detection by qualitative nested RT-PCR showed 76.1% sensitivity and 95% specificity. The overall sensitivity, specificity of urinary MMP zymography was 67.3%, 90% respectively. The combined use of urine cytology with urine survivin or MMPs zymography increased sensitivity of urine cytology from 50% to 84.7%. The highest sensitivity (95.6%) was obtained on combining the three markers. Conclusion: Survivin RNA and MMPS zymography can be considered as promising noninvasive markers for bladder cancer early detection. Combined use of the three markers improved the sensitivity for detecting bladder cancer.

show abstract

A Panel of Angiogenic Factors for Early Bladder Cancer Detection: Enzyme Immunoassay and Western Blot

Cited by 22 publications

References 10 publications

Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer

Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer

Aberrant Methylation ofRARβ2andAPCGenes in Voided Urine as Molecular Markers for Early Detection of Bilharzial and Nonbilharzial Bladder Cancer

The Value of Combined Use of Survivin mRNA and Matrix Metalloproteinase 2 and 9 for Bladder Cancer Detection in Voided Urine

Contact Info

Product

Resources

About